Biocompatibility of peritoneal dialysis fluids

Area of Science:

• Immunology
• Nephrology
• Biocompatibility

Background:

• Peritoneal dialysis (PD) solutions, particularly continuous ambulatory peritoneal dialysis (CAPD) fluids, have been shown to negatively impact immune cell functions.
• Studies indicate that these solutions reduce the viability and impair the phagocytic and bactericidal capacities of leukocytes and mesothelial cells.

Discussion:

• The inhibitory effects of CAPD fluids are linked to their low pH, high osmolality, and high glucose concentrations.
• While pH, glucose, and osmolality equilibrate partially in clinical settings, a temporary unphysiological environment compromises peritoneal host defense.
• Lactate may also suppress immune function, particularly at low pH.

Key Insights:

• CAPD solutions induce at least a temporary impairment of peritoneal host defense mechanisms.
• This impairment reflects the bioincompatibility of currently available CAPD fluids.
• Immune cell functions, such as cytokine production, can be affected even after prolonged intraperitoneal dwell times.

Outlook:

• There is a clear need to develop novel CAPD solutions with more physiological formulations.
• Optimizing PD fluid composition could enhance peritoneal defense and improve patient outcomes.
• Further research into the specific components of PD fluids and their immunomodulatory effects is warranted.